Erika Ferreira

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 32 citations · Full text

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

Peter A. Fasching, Aditya Bardia, Vanesa Quiroga et al. · Journal of Clinical Oncology · 2022 · 30 citations

Breast Oncology, Gynecology, Pharmacotherapy +22

Selective Cytotoxicity of Piperine over Multidrug Resistance Leukemic Cells

Julia Quarti, Daianne N. M. Torres, Erika Ferreira et al. · Molecules · 2021 · 15 citations · Full text

Chronic Myeloid Leukemia, Chemoprevention Strategy, Biochemistry +15

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in <i>ALK</i>-positive (<i>ALK</i>+) solid tumors in a histology-agnostic setting.

Razelle Kurzrock, Amy R. MacKenzie, Adham Jurdi et al. · Journal of Clinical Oncology · 2021 · 10 citations

Innovative Decentralized, Cancer Management, Immunology +17